A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Nichols, Eva-Maria; Jones, Rachel; Watson, Rachael; Pepper, Chris J; Fegan, Chris; Marchbank, Kevin J

Nichols, Eva-Maria; Jones, Rachel; Watson, Rachael; Pepper, Chris J; Fegan, Chris; Marchbank, Kevin J.

Affiliation

Nichols EM; Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.
Jones R; Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.
Watson R; Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.
Pepper CJ; Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, UK.
Fegan C; Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, UK.
Marchbank KJ; Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.

Oncotarget ; 6(32): 32669-80, 2015 Oct 20.

Article in En | MEDLINE | ID: mdl-26452134

Subject(s)
Key words

B cell; CD21; CLL; complement; poor prognosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Complement System Proteins / B-Lymphocytes / Leukemia, Lymphocytic, Chronic, B-Cell / Biomarkers, Tumor / Receptors, Complement 3d Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Oncotarget Year: 2015 Document type: Article Affiliation country: Reino Unido Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google